Calcium channel blockers may reduce the development of long COVID in females
© 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension..
With the rising numbers of patients infected with severe acute respiratory syndrome coronavirus 2, long coronavirus disease 2019 (COVID-19)-a sequelae of COVID-19-has become a major problem. Different sexes and age groups develop different long COVID symptoms, and the risk factors for long COVID remain unclear. Therefore, we performed subgroup analyses of patients with COVID-19, classifying them into different groups. In this multicenter cohort study, using an original questionnaire, we examined patients (≥18 years old) diagnosed with COVID-19 from November 2020 to March 2022 and hospitalized at participating medical facilities. In total, 1066 patients were registered (361 female, 620 male). Hypertension was the most common comorbidity (n = 344; 32.5%). Females with hypertension were significantly less likely to develop long COVID symptoms than those without hypertension (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.27-0.98; p = 0.043). In females, Ca channel blocker administration, rather than having hypertension, was significantly associated with reductions in the frequency of alopecia (OR 0.14, 95% CI 0.03-0.67, p = 0.015), memory impairment (OR 0.14, 95% CI 0.02-0.82, p = 0.029), sleeping disorders (OR 0.17, 95% CI 0.04-0.67, p = 0.012), tinnitus (OR 0.23, 95% CI 0.05-0.98, p = 0.047), sputum (OR 0.31, 95% CI 0.10-0.92, p = 0.035), and fever (OR 0.33, 95% CI 0.12-0.93, p = 0.036). Several long COVID symptoms, including alopecia, were significantly negatively associated with Ca channel-blocker administration in female patients with long COVID. Calcium channel blockers may reduce the development of long COVID in females.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - 47(2024), 4 vom: 01. Apr., Seite 934-943 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ozawa, Takuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihypertensive drug |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 23.04.2024 published: Print-Electronic CommentIn: Hypertens Res. 2024 Jan 31;:. - PMID 38297181 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41440-023-01501-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364697660 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364697660 | ||
| 003 | DE-627 | ||
| 005 | 20240424231857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41440-023-01501-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM364697660 | ||
| 035 | |a (NLM)37978232 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ozawa, Takuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Calcium channel blockers may reduce the development of long COVID in females |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hypertens Res. 2024 Jan 31;:. - PMID 38297181 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension. | ||
| 520 | |a With the rising numbers of patients infected with severe acute respiratory syndrome coronavirus 2, long coronavirus disease 2019 (COVID-19)-a sequelae of COVID-19-has become a major problem. Different sexes and age groups develop different long COVID symptoms, and the risk factors for long COVID remain unclear. Therefore, we performed subgroup analyses of patients with COVID-19, classifying them into different groups. In this multicenter cohort study, using an original questionnaire, we examined patients (≥18 years old) diagnosed with COVID-19 from November 2020 to March 2022 and hospitalized at participating medical facilities. In total, 1066 patients were registered (361 female, 620 male). Hypertension was the most common comorbidity (n = 344; 32.5%). Females with hypertension were significantly less likely to develop long COVID symptoms than those without hypertension (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.27-0.98; p = 0.043). In females, Ca channel blocker administration, rather than having hypertension, was significantly associated with reductions in the frequency of alopecia (OR 0.14, 95% CI 0.03-0.67, p = 0.015), memory impairment (OR 0.14, 95% CI 0.02-0.82, p = 0.029), sleeping disorders (OR 0.17, 95% CI 0.04-0.67, p = 0.012), tinnitus (OR 0.23, 95% CI 0.05-0.98, p = 0.047), sputum (OR 0.31, 95% CI 0.10-0.92, p = 0.035), and fever (OR 0.33, 95% CI 0.12-0.93, p = 0.036). Several long COVID symptoms, including alopecia, were significantly negatively associated with Ca channel-blocker administration in female patients with long COVID. Calcium channel blockers may reduce the development of long COVID in females | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antihypertensive drug | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Long COVID | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 700 | 1 | |a Kimura, Ryusei |e verfasserin |4 aut | |
| 700 | 1 | |a Terai, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Takemura, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Namkoong, Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Keitaro |e verfasserin |4 aut | |
| 700 | 1 | |a Yagi, Kazuma |e verfasserin |4 aut | |
| 700 | 1 | |a Asakura, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Masaki, Katsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Chubachi, Shotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Miyata, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Ohgino, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawada, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kagyo, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Odani, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwahara, Naota |e verfasserin |4 aut | |
| 700 | 1 | |a Nakachi, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunaga, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g 47(2024), 4 vom: 01. Apr., Seite 934-943 |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:934-943 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41440-023-01501-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2024 |e 4 |b 01 |c 04 |h 934-943 | ||